{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T06:18:23Z","timestamp":1780381103700,"version":"3.54.1"},"reference-count":40,"publisher":"Public Library of Science (PLoS)","issue":"10","license":[{"start":{"date-parts":[[2022,10,4]],"date-time":"2022-10-04T00:00:00Z","timestamp":1664841600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005972","name":"Deutsche Krebshilfe","doi-asserted-by":"publisher","award":["70111714"],"award-info":[{"award-number":["70111714"]}],"id":[{"id":"10.13039\/501100005972","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["428857858"],"award-info":[{"award-number":["428857858"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>Acute lymphoblastic leukemia (ALL) is a disease of lymphoid progenitor cells with an often aggressive course and is commonly caused by the BCR-ABL fusion gene t(9;22) in adults. This fusion gene encodes a constitutively active tyrosine kinase that can be effectively inhibited by tyrosine kinase inhibitors (TKIs), with imatinib being the paradigmatic agent of this class. However, BCR-ABL+ ALL cells rapidly develop mutations against many of the available TKIs, and consecutive disease relapse still results in an overall unfavorable prognosis for patients with this disease. To date, allogeneic stem cell transplantation is the only known curative therapeutic option for the mostly elderly patients with BCR-ABL+ ALL. The discrepancy between the limited therapeutic armamentarium and the growing therapeutic need in an aging population is therefore a reason to test drug combinations against BCR-ABL+ ALL. In this study, we demonstrate that the combination of TKIs with proteasome inhibitors efficiently and under certain conditions synergistically exerts cytotoxic effects in BCR-ABL+ ALL cells in vitro with respect to the induction of apoptosis. Both sole and combined treatment of BCR-ABL+ ALL with the proteasome inhibitors bortezomib and ixazomib, respectively, and TKI causes a significantly greater reduction in cell viability than TKI treatment alone in both BCR-ABL+ cell lines TOM-1 and BV-173. In BV-173 cells, we observed a significant reduction in cell viability to only 1.26%\u00b10.46% with bortezomib treatment and 1.57\u00b10.7% with combination treatment, whereas cells treated with dasatinib alone still had a viable percentage of 40.58\u00b12.6%. Similar results were obtained when ixazomib was applied to both cell lines, and apoptosis was induced in both cases (93.36%\u00b12.7% apoptotic BV-173 cells when treated with ixazomib and TKI). The combination of TKI and proteasome inhibitor is efficient in vitro, potentially expanding the spectrum of therapeutic options for patients with BCR-ABL+ ALL.<\/jats:p>","DOI":"10.1371\/journal.pone.0268352","type":"journal-article","created":{"date-parts":[[2022,10,4]],"date-time":"2022-10-04T17:29:21Z","timestamp":1664904561000},"page":"e0268352","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":4,"title":["Combined inhibition of BCR-ABL1 and the proteasome as a potential novel therapeutic approach in BCR-ABL positive acute lymphoblastic leukemia"],"prefix":"10.1371","volume":"17","author":[{"given":"Saskia","family":"Maletzke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azam","family":"Salimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margherita","family":"Vieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kema Marlen","family":"Schroeder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirle","family":"Schemionek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Behzad Kharabi","family":"Masouleh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim H.","family":"Br\u00fcmmendorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steffen","family":"Koschmieder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iris","family":"Appelmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2022,10,4]]},"reference":[{"issue":"1","key":"pone.0268352.ref001","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s40266-017-0503-5","article-title":"Treatment of Older Patients with Acute Lymphoblastic Leukaemia","volume":"35","author":"N. Gokbuget","year":"2018","journal-title":"Drugs Aging"},{"issue":"6","key":"pone.0268352.ref002","doi-asserted-by":"crossref","first-page":"e577","DOI":"10.1038\/bcj.2017.53","article-title":"Acute lymphoblastic leukemia: a comprehensive review and 2017 update","volume":"7","author":"T Terwilliger","year":"2017","journal-title":"Blood Cancer J"},{"key":"pone.0268352.ref003","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V126.23.4867.4867","article-title":"Philadelphia Positive Acute Lymphoblastic Leukemia, Tawam Experience","author":"A Alam","year":"2015","journal-title":"Blood"},{"issue":"25","key":"pone.0268352.ref004","doi-asserted-by":"crossref","first-page":"6521","DOI":"10.1182\/blood-2011-05-351403","article-title":"Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"118","author":"R Foa","year":"2011","journal-title":"Blood"},{"issue":"5","key":"pone.0268352.ref005","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s11912-012-0247-7","article-title":"Philadelphia-positive acute lymphoblastic leukemia: current treatment options","volume":"14","author":"T Liu-Dumlao","year":"2012","journal-title":"Curr Oncol Rep"},{"key":"pone.0268352.ref006","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s40880-016-0108-0","article-title":"The Philadelphia chromosome in leukemogenesis","volume":"35","author":"ZJ Kang","year":"2016","journal-title":"Chin J Cancer"},{"issue":"6","key":"pone.0268352.ref007","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1182\/blood-2016-02-700153","article-title":"Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome-positive ALL","volume":"128","author":"P Rousselot","year":"2016","journal-title":"Blood"},{"issue":"13","key":"pone.0268352.ref008","doi-asserted-by":"crossref","first-page":"3585","DOI":"10.1182\/blood-2010-08-301267","article-title":"Chemotherapeutic agents circumvent emergence of dasatinib-resistant BCR-ABL kinase mutations in a precise mouse model of Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"117","author":"N Boulos","year":"2011","journal-title":"Blood"},{"key":"pone.0268352.ref009","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1182\/asheducation-2009.1.371","article-title":"Management of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL)","author":"OG Ottmann","year":"2009","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"pone.0268352.ref010","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ddtec.2014.03.003","article-title":"Current aspects in resistance against tyrosine kinase inhibitors in chronic myelogenous leukemia","volume":"11","author":"S Balabanov","year":"2014","journal-title":"Drug Discov Today Technol"},{"issue":"7","key":"pone.0268352.ref011","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1182\/blood-2007-02-073528","article-title":"Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study","volume":"110","author":"O Ottmann","year":"2007","journal-title":"Blood"},{"issue":"10","key":"pone.0268352.ref012","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1002\/cncr.22631","article-title":"Imatinib compared with chemotherapy as front-line treatment of elderly patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL)","volume":"109","author":"OG Ottmann","year":"2007","journal-title":"Cancer"},{"issue":"4","key":"pone.0268352.ref013","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1038\/leu.2009.302","article-title":"Development of resistance to dasatinib in Bcr\/Abl-positive acute lymphoblastic leukemia","volume":"24","author":"F Fei","year":"2010","journal-title":"Leukemia"},{"issue":"4","key":"pone.0268352.ref014","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s10555-017-9699-4","article-title":"(Immuno)proteasomes as therapeutic target in acute leukemia","volume":"36","author":"J Cloos","year":"2017","journal-title":"Cancer Metastasis Rev"},{"issue":"21","key":"pone.0268352.ref015","doi-asserted-by":"crossref","first-page":"E2219","DOI":"10.1073\/pnas.1400958111","article-title":"Mechanistic rationale for targeting the unfolded protein response in pre-B acute lymphoblastic leukemia","volume":"111","author":"B Kharabi Masouleh","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"pone.0268352.ref016","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1042\/BJ20101293","article-title":"Regulation of unfolded protein response modulator XBP1s by acetylation and deacetylation","volume":"433","author":"FM Wang","year":"2011","journal-title":"Biochem J"},{"issue":"12","key":"pone.0268352.ref017","doi-asserted-by":"crossref","first-page":"4907","DOI":"10.1182\/blood-2005-08-3531","article-title":"Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells","volume":"107","author":"EA Obeng","year":"2006","journal-title":"Blood"},{"issue":"1","key":"pone.0268352.ref018","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3727\/105221610X12819686555051","article-title":"Emerging roles for XBP1, a sUPeR transcription factor","volume":"15","author":"Y He","year":"2010","journal-title":"Gene Expr"},{"key":"pone.0268352.ref019","article-title":"Targeting of BCR-ABL1 and IRE1alpha induces synthetic lethality in Philadelphia-positive acute lymphoblastic leukemia","author":"M Vieri","year":"2020","journal-title":"Carcinogenesis"},{"issue":"22","key":"pone.0268352.ref020","doi-asserted-by":"crossref","first-page":"4025","DOI":"10.2174\/1381612811319220012","article-title":"From bortezomib to other inhibitors of the proteasome and beyond","volume":"19","author":"D Buac","year":"2013","journal-title":"Curr Pharm Des"},{"issue":"7","key":"pone.0268352.ref021","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.3324\/haematol.2011.041392","article-title":"Bortezomib combined with rituximab and dexamethasone is an active regimen for patients with relapsed and chemotherapy-refractory mantle cell lymphoma","volume":"96","author":"W Lamm","year":"2011","journal-title":"Haematologica"},{"issue":"5","key":"pone.0268352.ref022","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S1470-2045(11)70081-X","article-title":"Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study","volume":"12","author":"P Moreau","year":"2011","journal-title":"Lancet Oncol"},{"issue":"7","key":"pone.0268352.ref023","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/nrclinonc.2016.206","article-title":"Proteasome inhibitors in cancer therapy","volume":"14","author":"EE Manasanch","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"issue":"6","key":"pone.0268352.ref024","doi-asserted-by":"crossref","first-page":"517","DOI":"10.2174\/1568009614666140804154511","article-title":"Overview of proteasome inhibitor-based anti-cancer therapies: perspective on bortezomib and second generation proteasome inhibitors versus future generation inhibitors of ubiquitin-proteasome system","volume":"14","author":"QP Dou","year":"2014","journal-title":"Curr Cancer Drug Targets"},{"issue":"12","key":"pone.0268352.ref025","doi-asserted-by":"crossref","first-page":"e0188680","DOI":"10.1371\/journal.pone.0188680","article-title":"Anti-leukemic activity of bortezomib and carfilzomib on B-cell precursor ALL cell lines","volume":"12","author":"K Takahashi","year":"2017","journal-title":"PLoS One"},{"issue":"4","key":"pone.0268352.ref026","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1111\/bjh.14505","article-title":"The combination of bortezomib with chemotherapy to treat relapsed\/refractory acute lymphoblastic leukaemia of childhood","volume":"176","author":"A Bertaina","year":"2017","journal-title":"Br J Haematol"},{"issue":"6","key":"pone.0268352.ref027","doi-asserted-by":"crossref","first-page":"552","DOI":"10.4161\/cbt.11.6.14675","article-title":"Bortezomib treatment causes remission in a Ph+ALL patient and reveals FoxO as a theranostic marker","volume":"11","author":"R Dewar","year":"2011","journal-title":"Cancer Biol Ther"},{"issue":"16","key":"pone.0268352.ref028","doi-asserted-by":"crossref","first-page":"3459","DOI":"10.1182\/blood-2007-10-113969","article-title":"Acute dasatinib exposure commits Bcr-Abl-dependent cells to apoptosis","volume":"114","author":"JL Snead","year":"2009","journal-title":"Blood"},{"issue":"50","key":"pone.0268352.ref029","doi-asserted-by":"crossref","first-page":"33533","DOI":"10.1074\/jbc.273.50.33533","article-title":"Importance of poly(ADP-ribose) polymerase and its cleavage in apoptosis. Lesson from an uncleavable mutant","volume":"273","author":"FJ Oliver","year":"1998","journal-title":"J Biol Chem"},{"issue":"4","key":"pone.0268352.ref030","doi-asserted-by":"crossref","first-page":"e0123341","DOI":"10.1371\/journal.pone.0123341","article-title":"The pro-apoptotic BH3-only protein Bim interacts with components of the translocase of the outer mitochondrial membrane (TOM)","volume":"10","author":"DO Frank","year":"2015","journal-title":"PLoS One"},{"issue":"4","key":"pone.0268352.ref031","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1080\/01926230701320337","article-title":"Apoptosis: a review of programmed cell death","volume":"35","author":"S. Elmore","year":"2007","journal-title":"Toxicol Pathol"},{"issue":"2","key":"pone.0268352.ref032","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1182\/blood-2012-04-418640","article-title":"Bortezomib with chemotherapy is highly active in advanced B-precursor acute lymphoblastic leukemia: Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study","volume":"120","author":"YH Messinger","year":"2012","journal-title":"Blood"},{"issue":"1","key":"pone.0268352.ref033","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bcp.2015.04.008","article-title":"Proteasome inhibitors","volume":"96","author":"BA Teicher","year":"2015","journal-title":"Biochem Pharmacol"},{"issue":"17","key":"pone.0268352.ref034","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1056\/NEJMoa2016272","article-title":"Dasatinib-Blinatumomab for Ph-Positive Acute Lymphoblastic Leukemia in Adults","volume":"383","author":"R Fo\u00e0","year":"2020","journal-title":"N Engl J Med"},{"issue":"5","key":"pone.0268352.ref035","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1002\/ajh.23419","article-title":"Apoptosis in chronic myeloid leukemia cells transiently treated with imatinib or dasatinib is caused by residual BCR-ABL kinase inhibition","volume":"88","author":"P Simara","year":"2013","journal-title":"Am J Hematol"},{"issue":"4","key":"pone.0268352.ref036","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1002\/ijc.20793","article-title":"Bortezomib is an efficient agent in plasma cell leukemias","volume":"114","author":"A Esparis-Ogando","year":"2005","journal-title":"Int J Cancer"},{"issue":"15","key":"pone.0268352.ref037","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.1002\/cncr.30558","article-title":"Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosome-positive leukemias with the T315I mutation","volume":"123","author":"FE Nicolini","year":"2017","journal-title":"Cancer"},{"issue":"9","key":"pone.0268352.ref038","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1182\/blood-2014-09-601062","article-title":"Janus kinase inhibition by ruxolitinib extends dasatinib- and dexamethasone-induced remissions in a mouse model of Ph+ ALL","volume":"125","author":"I Appelmann","year":"2015","journal-title":"Blood"},{"issue":"9","key":"pone.0268352.ref039","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/j.exphem.2010.04.017","article-title":"Establishment of a new Philadelphia chromosome-positive acute lymphoblastic leukemia cell line (SK-9) with T315I mutation","volume":"38","author":"S Okabe","year":"2010","journal-title":"Exp Hematol"},{"issue":"1","key":"pone.0268352.ref040","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1186\/s12885-017-3511-2","article-title":"The clonal evolution of two distinct T315I-positive BCR-ABL1 subclones in a Philadelphia-positive acute lymphoblastic leukemia failing multiple lines of therapy: a case report","volume":"17","author":"C De Benedittis","year":"2017","journal-title":"BMC Cancer"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0268352","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,4]],"date-time":"2022-10-04T17:29:57Z","timestamp":1664904597000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0268352"}},"subtitle":[],"editor":[{"given":"Persio","family":"Dello Sbarba","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2022,10,4]]},"references-count":40,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2022,10,4]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0268352","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,4]]}}}